Bladder Cancer Studies Currently Recruiting Participants at the University of Chicago Comprehensive Cancer Center

	Study Number	Title
Select	11-0646	S1011: A Phase III Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radial Cystectomy for Muscle Invasive Urothelial Cancer
	11-0719	AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0980 ADMINISTERED ONCE DAILY IN PATIENTS WITH REFRACTORY SOLID TUMORS OR NON-HODGKIN�S LYMPHOMA
	13-0311	A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors
	12278A	Clinical Urology Research Screening Protocol
Select	14578A	A Phase I/II Study of E7389 Halichondrin B analog (NSC# 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
	15550B	Bladder Cancer Sample Collection
Select	09-152-B	CALGB 90601: A randomized double-blinded phase III study comparing gemcitabine, cisplatin, and bevacizumab (IND #7921, NSC #704865) to gemcitabine, cislpatin, and placebo in patients with Advanced transitional cell carcinoma
Select	09-288-B	Identification of genetic determinants of response to neoadjuvant cisplatin-based chemotherapy in urothelial cancer
Select	10-017-B	A Phase I Open Label Single Center Exploratory Study of an Autologous Neo-Urinary Conduit in Subjects Requiring Incontinent Urinary Diversion Following Radical Cycstectomy
	10-151-B	Prospective Multi-Center Evaluation of High Grade T1 Bladder Cancer Protocol
Select	11-0106	A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
	10-153-B	Multi-institutional evaluation and quality of care initiative for the management of muscle invasive bladder cancer

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.